#BEGIN_DRUGCARD DB00923

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DC11

# Absorption:
Rapidly absorbed following intramuscular injection.

# Biotransformation:
The major drug elimination route was urinary excretion with 85% of the dose being excreted unchanged in the urine within 12 hr, and no metabolites with antibiotic activity were observed in urine.

# Brand_Mixtures:
Not Available

# Brand_Names:
Precef

# CAS_Registry_Number:
60925-61-3

# ChEBI_ID:
3495

# Chemical_Formula:
C20H21N7O6S2

# Chemical_IUPAC_Name:
(6R,7R)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Ceforanide is a second-generation parenteral cephalosporin antibiotic. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Amikacin	Increased risk of nephrotoxicity
Gentamicin	Increased risk of nephrotoxicity
Netilmicin	Increased risk of nephrotoxicity
Tobramycin	Increased risk of nephrotoxicity

# Drug_Reference:
3140456	Crowle AJ, Sbarbaro JA, May MH: Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. Tubercle. 1988 Mar;69(1):15-25.
3315624	Campoli-Richards DM, Lackner TE, Monk JP: Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1987 Oct;34(4):411-37.
3814386	Cone LA, Barton SM, Woodard DR: Treatment of scleroma with ceforanide. Arch Otolaryngol Head Neck Surg. 1987 Apr;113(4):374-6.
6762529	Barriere SL, Mills J: Ceforanide: antibacterial activity, pharmacology, and clinical efficacy. Pharmacotherapy. 1982 Nov-Dec;2(6):322-7.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ceforanide

# HET_ID:
Not Available

# Half_Life:
2.6 to 2.98 hours

# InChI_Identifier:
InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1

# InChI_Key:
InChIKey=SLAYUXIURFNXPG-CRAIPNDOSA-N

# Indication:
For the treatment of infections caused by susceptible organisms.

# KEGG_Compound_ID:
C06884

# KEGG_Drug_ID:
D00259

# LIMS_Drug_ID:
923

# Mechanism_Of_Action:
The bactericidal activity of ceforanide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
519.554

# Molecular_Weight_Mono:
519.099472819

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746057

# Pharmacology:
Ceforanide is a semisynthetic second-generation cephalosporin. The cephalosporins are bactericidal drugs with both gram-positive and gram-negative activity. They inhibit bacterial cell wall synthesis in a way similar to the penicillins.

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.97e-01 g/l

# Primary_Accession_No:
DB00923

# Protein_Binding:
80.6%

# PubChem_Compound_ID:
43507

# PubChem_Substance_ID:
46504532

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00853

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Ceforanido [INN-Spanish]
Ceforanidum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.

# Update_Date:
2013-02-08 16:19:45 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ceforanide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
3266730	Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53.
6762529	Barriere SL, Mills J: Ceforanide: antibacterial activity, pharmacology, and clinical efficacy. Pharmacotherapy. 1982 Nov-Dec;2(6):322-7.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AP006841

# Drug_Target_1_GenBank_ID_Protein:
52214157

# Drug_Target_1_GeneCard_ID:
pbpA

# Drug_Target_1_Gene_Name:
pbpA

# Drug_Target_1_Gene_Sequence:
>528 bp
ATGCGAAAATTGAAAATAACCGAGCTGAACCGGATAAGTATAGAAGAGTTTAAAGAAGCT
GATAAATTGCCTTTAGTTGTAGTGTTGGACGATATACGGAGTTTGCATAATATCGGTTCT
GTGTTTCGTACGGCAGATGCTTTCCGGATTGAATGTATTTATCTGTGTGGAATTACGGCT
ACTCCTCCCCATCCCGAGATGCATAAGACAGCTTTGGGAGCCGAGTTTACAGTGGATTGG
AAGTATGTTAATAACGCAGTTGAAACGGTTGATAACCTCCGGAGTGAAGGATATGTGGTA
TACTCTGTCGAACAGGCGGAGGGGAGTATCATGTTGGATGAGTTAACACTGGACCGTTCG
AAGAAATATGCTGTAGTTATGGGAAATGAAGTAAAAGGAGTGCAGCAGGAGGTTATTGAC
CATTCGGATGGTTGTATTGAGATTCCCCAATATGGCACAAAACATTCATTGAATGTATCG
GTAACAGCAGGAATTGTGATCTGGGATTTATTTAAAAAGTTGAAATAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
15466707	Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N, Kuhara S, Hattori M, Hayashi T, Ohnishi Y: Genomic analysis of Bacteroides fragilis reveals extensive DNA inversions regulating cell surface adaptation. Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14919-24. Epub 2004 Oct 4.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6187

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
69434.3

# Drug_Target_1_Name:
Penicillin-binding protein 2

# Drug_Target_1_Number_of_Residues:
618

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2
MAKDYVLEKRKYVIGGVALAIVLIYLLRLFSLQIATDDYKKNADSNAFLNKIQYPSRGAM
YDRNDKLLVFNQPAYDITMVPKEVENLDTLDLCQTLNITRAQFLKIMSDMKDRRRNPGYS
RYTNQVFMSQLSAEECGVFQEKLFKFHGFYIQRRTIRQYSYNSAAHVLGDIGEVSMKDIE
NDDYYIRGDYIGKQGIEKSYESYLRGEKGVEVLLRDAHGRIQGHYMDGKYDKRPIPGKNL
KLGIDIDLQMLGERLLKNKIGSIVAIEPETGEILCMVSSPDFDPRLMIGRQRGKNHLMLQ
RDPMKPLLNRSIMGVYPPGSTFKTAQALTFLQEGIIQTNTPAFPCAHGFNYGSLHVGCHA
HGSPLPLIPAIATSCNSYFCWGLFRMFGDRKYGSSQNAITVWKDHMVSQGFGYKLGVDLP
GEKRGLIPNAQFYDKAYRGRWNGLTVISIAIGQGEILATPLQIANLGATIANRGHFITPH
IVKEIQDEQLDSLYRVPRKTSIDRKHYEDVVTGMRAAVTGGTCRVAGAILPDVEVCGKTG
TAQNRGHDHSVFMGFAPMNNPKIAIAVYVENGGFGAVYGVPIGALMMEQYLKGKLSPENE
IRAEEYSNRVIMYGNEER

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q70KI2

# Drug_Target_1_SwissProt_Name:
Q70KI2_BACFR

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
8.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00923
